Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.
View Top Employees from VaxcyteWebsite | http://vaxcyte.com/ |
Ticker | PCVX |
Revenue | $60.8 million |
Funding | $381 million |
Employees | 278 (188 on RocketReach) |
Founded | 2013 |
Address | 825 Industrial Rd Suite 300, San Carlos, California 94070, US |
Phone | (650) 837-0111 |
Industry | Biotechnology Research, Pharmaceuticals, Biopharma, Healthcare, Biotechnology, Health Care, Science and Engineering |
Web Rank | 12 Million |
Keywords | Why Do Conjugate Vaccines Produce Igg Response |
Competitors | AlphaVax, Dynavax Technologies, Epitopix, Genocea, Virótica Digital |
SIC | SIC Code 87 Companies, SIC Code 873 Companies, SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325414 Companies, NAICS Code 54 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 541 Companies |
Looking for a particular Vaxcyte employee's phone or email?
The Vaxcyte annual revenue was $60.8 million in 2024.
Andrew Guggenhime is the President and Chief Financial Officer of Vaxcyte.
188 people are employed at Vaxcyte.
Vaxcyte is based in San Carlos, California.
The NAICS codes for Vaxcyte are [325414, 54, 325, 32, 32541, 3254, 541].
The SIC codes for Vaxcyte are [87, 873, 283, 28].